CORT (Corcept Therapeutics Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CORT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | William Guyer | Chief Development Officer | A | — | — |
| 2026-09-03 | Gary Charles Robb | Chief Business Officer | MIXED | — | — |
| 2026-09-03 | Joseph Douglas Lyon | See Remarks | MIXED | — | — |
| 2026-09-03 | Atabak Mokari | Chief Financial Officer | MIXED | — | — |
| 2026-09-03 | Roberto Wandenkolk Vieira | President, Oncology | MIXED | — | — |
| 2026-09-03 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-08-28 | Kimberly Park | Director | MIXED | — | — |
| 2026-08-27 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-08-20 | DAVID L MAHONEY | Director | Sell | — | — |
| 2026-08-18 | Gary Charles Robb | Chief Business Officer | MIXED | — | — |
| 2026-08-18 | JAMES N WILSON | Director | Sell | — | — |
| 2026-08-18 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-08-14 | Gary Charles Robb | Chief Business Officer | G | — | — |
| 2026-08-12 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-08-12 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-08-06 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-08-06 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-08-05 | Joseph Douglas Lyon | See Remarks | Sell | — | — |
| 2026-08-05 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-08-03 | Atabak Mokari | Chief Financial Officer | MIXED | — | — |
| 2026-07-17 | Atabak Mokari | Chief Financial Officer | MIXED | — | — |
| 2026-07-17 | JAMES N WILSON | Director | Sell | — | — |
| 2026-07-08 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-07-08 | Gary Charles Robb | Chief Business Officer | G | — | — |
| 2026-07-06 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-06-18 | DAVID L MAHONEY | Director | Sell | — | — |
| 2026-06-18 | JAMES N WILSON | Director | Sell | — | — |
| 2026-06-17 | Atabak Mokari | Chief Financial Officer | MIXED | — | — |
| 2026-06-04 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-06-03 | Gary Charles Robb | Chief Business Officer | MIXED | — | — |
| 2026-06-03 | Atabak Mokari | Chief Financial Officer | MIXED | — | — |
| 2026-06-03 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-06-03 | William Guyer | Chief Development Officer | A | — | — |
| 2026-06-03 | Joseph Douglas Lyon | See Remarks | MIXED | — | — |
| 2026-06-02 | JOSEPH K BELANOFF | Chief Executive Officer | MIXED | — | — |
| 2026-05-29 | JAMES N WILSON | Director | G | — | — |
| 2026-05-29 | Sean Maduck | See Remarks | MIXED | — | — |
| 2026-05-29 | Joseph Douglas Lyon | See Remarks | Sell | — | — |
| 2026-05-26 | Kimberly Park | Director | A | — | — |
| 2026-05-26 | DAVID L MAHONEY | Director | A | — | — |
| 2026-05-26 | Joshua M. Murray | Director | A | — | — |
| 2026-05-26 | Daniel N Swisher JR | Director | A | — | — |
| 2026-05-26 | JAMES N WILSON | Director | A | — | — |
| 2026-05-26 | Gregg H Alton | Director | A | — | — |
| 2026-05-26 | G LEONARD BAKER JR | Director | A | — | — |
| 2026-05-15 | Gary Charles Robb | Chief Business Officer | G | — | — |
| 2026-05-07 | William Guyer | Chief Development Officer | MIXED | — | — |
| 2026-05-05 | JOSEPH K BELANOFF | Chief Executive Officer | Sell | — | — |
| 2026-04-24 | JAMES N WILSON | Director | G | — | — |
| 2026-04-08 | JAMES N WILSON | Director | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 14,537,385 | — |
| — | 10%+ Owner | 14,113,304 | — |
| — | Director | 13,970,991 | — |
| — | Director | 10,874,259 | — |
| — | Director | 5,993,653 | — |
| — | 10%+ Owner | 5,664,267 | — |
| — | 10%+ Owner | 5,664,267 | — |
| — | Director | 5,525,313 | — |
| — | 10%+ Owner | 5,357,046 | — |
| — | 10%+ Owner | 5,336,053 | — |
| — | 10%+ Owner | 5,314,616 | — |
| — | 10%+ Owner | 5,043,299 | — |
| — | 10%+ Owner | 5,036,602 | — |
| — | Director | 4,454,934 | — |
| — | Director | 2,492,887 | — |
| — | Director | 2,438,749 | — |
| — | Director | 1,163,939 | — |
| — | Director | 1,074,543 | — |
| — | 10%+ Owner | 880,564 | — |
| — | SVP Oncology | 585,416 | — |
| — | Chief Executive Officer | 393,154 | — |
| — | 10%+ Owner | 327,603 | — |
| — | Chief Scientific Officer | 255,437 | — |
| — | 10%+ Owner | 242,210 | — |
| — | Director | 209,694 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CORT quote page; the site-wide leaderboard is on the insider transactions hub.